CD45BE-HSPC + CART-45 Cells
Plain-language summary
This trial is testing CAR-T cell therapy (genetically modified immune cells) for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. Patients are randomly assigned to different treatment groups. The study looks at both safety and how well the treatment controls the lymphoma. This trial is available at 1 location in the United States.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
CART-45 cells (BIOLOGICAL): Autologous base edited anti-CD45 CAR T cells | CD45BE-HSPC (BIOLOGICAL): CD45 base edited hematopoietic stem and progenitor cells
CART-45 cells, CD45BE-HSPC
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details